Could this FTSE 100 stock double your money again?

G A Chester discusses the outlook for this FTSE 100 (INDEXFTSE:UKX) big winner and a smaller-cap peer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors who bought into the Hikma Pharmaceuticals(LSE: HIK) turnaround story at the lows early last year doubled their money before the year was out. The shares have since retreated from their peak, and are off another few percentage points today after the FTSE 100 firm’s annual results.

However, could the stock be set for another big upsurge, alongside small-cap peer Alliance Pharma (LSE: APH), whose shares have seen an even bigger pullback since soaring last year?

Growth across the board

Hikma posted strong results today. These followed leadership changes and a major overhaul of the business, including the consolidation of its Generics manufacturing facilities and US distribution facilities.

Group revenue increased 7% to $2.1bn, with core operating profit up 19% to $460m, and core earnings per share (EPS) rising 31% to $1.378 (104.4p at current exchange rates). The board lifted the dividend 12% to $0.38 (28.8p).

All three of its businesses — Injectables, Generics and Branded — increased their revenues and profits. And there was growth across all three of its geographical regions: US (62% of group revenue); Middle East and North Africa (32%); and Europe and Rest of World (6%).

Very optimistic

Hikma’s shares are trading at 1,580p, as I’m writing, which is 22% below last year’s high of 2,025p. The trailing price-to-earnings (P/E) ratio is 15.1 and the dividend yield is 1.8%. While the yield is admittedly skinny, the P/E is reasonable for a blue-chip stock in the defensive pharma sector.

Furthermore, Hikma’s transformational changes and strong performance in 2018 have new chief executive Siggi Olafsson “confident that we can build on this momentum going forward,” and executive chairman Said Darwazah “very optimistic for the future.”

I can’t see Hikma’s shares doubling again in the space of a year, but with the business back on track, the longer-term outlook appears promising. I rate the stock a ‘buy’.

Unmerited de-rating

Alliance Pharma has a growing portfolio of pharmaceutical and consumer healthcare products it owns or licenses the rights to. It sells these products in more than 100 countries.

Its shares are trading at 65p, down 36% from last year’s high of 102p. I’m at a loss to understand quite why the stock has slumped so far. A £0.7m step-up in its future annual cost base, due to a raft of regulatory and accounting changes, hardly seems sufficient to merit such a de-rating. There was a hefty share sale by company founder (and now a non-executive director) John Dawson in November, but the shares had already completed much of their decline by that date.

Further growth ahead

In a trading update in January, ahead of annual results scheduled for release a week on Tuesday, Alliance said 2018 revenue was £124m — up 22% on the prior year, or up 4% excluding acquisitions. It also said “underlying profit before tax is expected to be in line with [unspecified] expectations” and that “free cash flow for the year was slightly stronger than anticipated at approximately £16.1m.”

A research note dated November on its corporate website has underlying profit before tax of £28.9m, free cash flow of £15.5m, underlying EPS of 4.66p (10% ahead of 2017), and a dividend of 1.46p (also up 10%). At the current share price, the P/E is 13.9 and the dividend yield is 2.25%.

I see the shares as very buyable, with the company having said in January: “We look forward to delivering further growth in the year ahead.”

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Alliance Pharma and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »